Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance.
[Arg(8)]-vasopressin (AVP) is involved in the regulation of glucose homeostasis via vasopressin V(1A) and vasopressin V(1B) receptor. Our previous studies have demonstrated that vasopressin V(1A) receptor deficient (V(1A)R(-/-)) mice exhibited hyperglycemia, vasopressin V(1B) receptor deficient (V(1B)R(-/-)) mice, in contrast, exhibited hypoglycemia with hypoinsulinemia. These findings indicate that vasopressin V(1A) receptor deficiency results in decreased insulin sensitivity, whereas vasopressin V(1B) receptor deficiency results in increased insulin sensitivity. In our previous and present studies, we used the glucose tolerance test to investigate glucose tolerance in mutant mice, lacking either the vasopressin V(1A) receptor, the vasopressin V(1B) receptor, or both receptors, that were kept on a high-fat diet. Glucose and insulin levels were lower in V(1B)R(-/-) mice than in wild type (WT) mice when both groups were fed the high-fat diet, which indicates that the insulin sensitivity of the V(1B)R(-/-) mice was enhanced. V(1A)R(-/-) mice on the high-fat diet, on the other hand, exhibited overt obesity, along with an impaired glucose tolerance, while WT mice on the high-fat diet did not. Next, in order to assess the effect of vasopressin V(1B) receptor deficiency on the development of glucose intolerance caused by vasopressin V(1A) receptor deficiency, we generated mice that were deficient for both vasopressin V(1A) receptor and vasopressin V(1B) receptor (V(1AB)R(-/-)), fed them a high-fat diet, and examined their glucose tolerances using the glucose tolerance test. Glucose tolerance was impaired in V(1AB)R(-/-) mice, suggesting that the effects of vasopressin V(1B) receptor deficiency could not influence the development of hyperglycemia promoted by vasopressin V(1A) receptor deficiency, and that blockade of both receptors could lead to impaired glucose tolerance.
Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan.
Kazuaki
K
Nakamura
Toshinori
T
Aoyagi
Masami
M
Hiroyama
Shinji
S
Kusakawa
Reiko
R
Mizutani
Atsushi
A
Sanbe
Junji
J
Yamauchi
Masazumi
M
Kamohara
Kazuhiro
K
Momose
Akito
A
Tanoue
D052438:Adipocytes, White / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D004041:Dietary Fats / Q000494:pharmacology; D002149:Energy Intake; D018149:Glucose Intolerance / Q000378:metabolism* / Q000503:physiopathology; D006706:Homeostasis / Q000187:drug effects; D007328:Insulin / Q000494:pharmacology; D008297:Male; D051379:Mice; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D017483:Receptors, Vasopressin / Q000172:deficiency* / Q000378:metabolism*
D001786:Blood Glucose; D004041:Dietary Fats; D007328:Insulin; D017483:Receptors, Vasopressin; D051057:Proto-Oncogene Proteins c-akt